Literature DB >> 30108967

A peptide inhibitor of antibody-dependent cell-mediated cytotoxicity against EGFR/folate receptor-α double positive cells.

Koichi Sasaki1, Yoshiki Miyashita1, Daisuke Asai2, Daiki Funamoto1, Kazuki Sato3, Yoko Yamaguchi3, Yuji Mishima4, Tadafumi Iino5, Shigeo Takaishi5, Jun Nagano6, Akihiro Kishimura1, Takeshi Mori1, Yoshiki Katayama1.   

Abstract

Antibody-dependent cell-mediated cytotoxicity (ADCC) is caused by natural killer (NK) cells upon recognition of antigen-bound IgG via FcγRIIIa. This mechanism is crucial for cytolysis of pathogen-infected cells and monoclonal antibody (mAb)-mediated elimination of cancer cells. However, there is concern that mAb-based cancer therapy induces ADCC against non-target cells expressing antigens. To date, no strategy has been reported to enhance the selectivity of ADCC to protect non-target cells expressing antigens. Here, we introduce a model inhibitor which specifically blocks ADCC of anti-EGFR mAbs towards EGFR/folate receptor α (FRα) double positive cells. This inhibitor recruits mAbs on the FRα of the cell surface independent of Fab antigen recognition. The resulting ternary and/or quaternary complexes formed on the cell surface suppress signal transduction of FcγRIIIa in NK cells, consequently leading to more specific ADCC.

Entities:  

Year:  2018        PMID: 30108967      PMCID: PMC6072457          DOI: 10.1039/c8md00010g

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  19 in total

1.  Convergent solutions to binding at a protein-protein interface.

Authors:  W L DeLano; M H Ultsch; A M de Vos; J A Wells
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

Review 2.  Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy.

Authors:  Hala Elnakat; Manohar Ratnam
Journal:  Adv Drug Deliv Rev       Date:  2004-04-29       Impact factor: 15.470

3.  Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases.

Authors:  R Trotta; K A Puorro; M Paroli; L Azzoni; B Abebe; L C Eisenlohr; B Perussia
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

4.  Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.

Authors:  Takumi Kumai; Kensuke Oikawa; Naoko Aoki; Shoji Kimura; Yasuaki Harabuchi; Hiroya Kobayashi
Journal:  Head Neck       Date:  2015-05-26       Impact factor: 3.147

5.  Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.

Authors:  Cristina Capuano; Maddalena Romanelli; Chiara Pighi; Giuseppe Cimino; Angela Rago; Rosa Molfetta; Rossella Paolini; Angela Santoni; Ricciarda Galandrini
Journal:  Cancer Res       Date:  2015-07-30       Impact factor: 12.701

6.  Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity.

Authors:  Jennifer T Grier; Lisa R Forbes; Linda Monaco-Shawver; Jennifer Oshinsky; T Prescott Atkinson; Curtis Moody; Rahul Pandey; Kerry S Campbell; Jordan S Orange
Journal:  J Clin Invest       Date:  2012-09-24       Impact factor: 14.808

7.  The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.

Authors:  Julie M Roda; Trupti Joshi; Jonathan P Butchar; Jaclyn W McAlees; Amy Lehman; Susheela Tridandapani; William E Carson
Journal:  Clin Cancer Res       Date:  2007-10-25       Impact factor: 12.531

8.  Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.

Authors:  Sri Vidya Kondadasula; Julie M Roda; Robin Parihar; Jianhua Yu; Amy Lehman; Michael A Caligiuri; Susheela Tridandapani; Richard W Burry; William E Carson
Journal:  Blood       Date:  2008-01-03       Impact factor: 22.113

Review 9.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

10.  Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents.

Authors:  Bong-Ha Shin; Shili Ge; James Mirocha; Artur Karasyov; Ashley Vo; Stanley C Jordan; Mieko Toyoda
Journal:  Transplantation       Date:  2014-02-15       Impact factor: 4.939

View more
  2 in total

1.  Induction of ADCC by a folic acid-mAb conjugate prepared by tryptophan-selective reaction toward folate-receptor-positive cancer cells.

Authors:  Hiroshi Tagawa; Katsuya Maruyama; Koichi Sasaki; Natsuki Konoue; Akihiro Kishimura; Motomu Kanai; Takeshi Mori; Kounosuke Oisaki; Yoshiki Katayama
Journal:  RSC Adv       Date:  2020-04-29       Impact factor: 4.036

Review 2.  DNA-assisted site-selective protein modification.

Authors:  Jordi F Keijzer; Bauke Albada
Journal:  Biopolymers       Date:  2021-12-08       Impact factor: 2.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.